Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Agostinetto

Showing results (11-20 of 76) with videos related to

Pageof 8
Sort By:
Immunotargets and Therapy|June 30, 2021
VISTA: A Promising Target for Cancer Immunotherapy?Marco Tagliamento, Elisa Agostinetto, Roberto Borea, et al.
European Journal of Clinical Investigation|March 4, 2021
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancerElisa Agostinetto, Véronique Debien, Guilherme Nader Marta, et al.
Critical Reviews in Oncology/Hematology|March 2, 2019
Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?Rosalba Torrisi, Monica Zuradelli, Elisa Agostinetto, et al.
Journal of Clinical Medicine|March 11, 2023
Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with AbemaciclibFlavia Jacobs, Elisa Agostinetto, Alessandra Solferino, et al.
Critical Reviews in Oncology/Hematology|March 5, 2021
Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?Rosalba Torrisi, Emilia Marrazzo, Elisa Agostinetto, et al.
Cancers|July 2, 2021
HER2-Low Breast Cancer: Molecular Characteristics and PrognosisElisa Agostinetto, Mattia Rediti, Danai Fimereli, et al.
Future Oncology (London, England)|August 23, 2023
DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancerVéronique Debien, Virginie Adam, Elisabeth Coart, et al.
Future Oncology (London, England)|September 13, 2016
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in ItalyFabio Puglisi, Elisa Agostinetto, Lorenzo Gerratana, et al.
International Journal of Molecular Sciences|April 30, 2021
Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental ModelsAlessio Gerussi, Ambra Natalini, Fabrizio Antonangeli, et al.
Breast Care (Basel, Switzerland)|January 2, 2023
HER2-Low Breast Cancer: Where Are We?Chiara Molinelli, Flavia Jacobs, Caterina Marchiò, et al.
Pageof 8

Showing results (11-20 of 76) with videos related to

Sort By:
Pageof 8
Immunotargets and Therapy|June 30, 2021
VISTA: A Promising Target for Cancer Immunotherapy?Marco Tagliamento, Elisa Agostinetto, Roberto Borea, et al.
European Journal of Clinical Investigation|March 4, 2021
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancerElisa Agostinetto, Véronique Debien, Guilherme Nader Marta, et al.
Critical Reviews in Oncology/Hematology|March 2, 2019
Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?Rosalba Torrisi, Monica Zuradelli, Elisa Agostinetto, et al.
Journal of Clinical Medicine|March 11, 2023
Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with AbemaciclibFlavia Jacobs, Elisa Agostinetto, Alessandra Solferino, et al.
Critical Reviews in Oncology/Hematology|March 5, 2021
Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?Rosalba Torrisi, Emilia Marrazzo, Elisa Agostinetto, et al.
Cancers|July 2, 2021
HER2-Low Breast Cancer: Molecular Characteristics and PrognosisElisa Agostinetto, Mattia Rediti, Danai Fimereli, et al.
Future Oncology (London, England)|August 23, 2023
DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancerVéronique Debien, Virginie Adam, Elisabeth Coart, et al.
Future Oncology (London, England)|September 13, 2016
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in ItalyFabio Puglisi, Elisa Agostinetto, Lorenzo Gerratana, et al.
International Journal of Molecular Sciences|April 30, 2021
Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental ModelsAlessio Gerussi, Ambra Natalini, Fabrizio Antonangeli, et al.
Breast Care (Basel, Switzerland)|January 2, 2023
HER2-Low Breast Cancer: Where Are We?Chiara Molinelli, Flavia Jacobs, Caterina Marchiò, et al.
Pageof 8